A dual GLP-1 and GIP receptor agonist used for type 2 diabetes and obesity, enhancing insulin secretion, suppressing glucagon, and promoting weight loss.
Minnetti. Marianna M; Barazzoni. Rocco R; Batsis. John A JA; Busetto. Luca L; Yumuk. Volkan V; Poggi...
Tirzepatide and similar drugs can shrink your waist fast, but they don't protect muscle or stop nutrient gaps. Simple advice like "eat healthy and move more" helps stop weight gain, but once you're already overweight you need a custom diet and workout plan. Mixing tirzepatide with a personalized nutrition and exercise program gives the best chance to lose fat, keep muscle, and stay healthy long‑term.
Koceva. Andrijana A; Janež. Andrej A; Jensterle. Mojca M
This review says that losing weight before getting pregnant is important, and drugs like tirzepatide that target GLP‑1 and GIP can help women with obesity lose weight. However, there isn’t solid safety data for using these drugs during early pregnancy, so they should be stopped before trying to conceive and avoided if pregnancy occurs unexpectedly. The paper highlights the need for careful planning and medical oversight when considering these meds for pre‑conception weight loss.
Khalil. Amina A; Velikyan. Irina I; Xiong. Mengfei M; Bossart. Martin M; Wagner. Michael M; Eriksson...
A PET scan study in pigs showed that tirzepatide does bind to the gut hormone receptor GLP‑1R in the pancreas, but it reaches the brain much less than a newer triple‑agonist drug (SAR441255). The triple‑agonist also hits the GIP receptor in the pancreas. This suggests tirzepatide’s main action is outside the brain, while stronger brain engagement may need different compounds or higher doses.
Galindo. Rodolfo J RJ; Cheng. Alice Y Y AYY; Longuet. Christine C; Ai. Minrong M; Coskun. Tamer T; M...
Tirzepatide is a new drug that activates two gut hormones (GIP and GLP‑1) to lower blood sugar, help people lose weight, and may improve heart and liver health. The review explains how it works and highlights early evidence that it could help with heart failure, fatty liver disease, and possibly sleep apnea, but big outcome studies are still pending.
Song. Zihang Z; Tang. Yifan Y; Peng. Mao M; Han. Ruoyu R; He. Pingping P
The paper looks at how your DNA might change the way you respond to tirzepatide, a new drug that helps lower blood sugar, cut weight, and protect the heart. It gathers what we know so far about genetic differences that can make the drug work better or cause more side‑effects, and talks about how this could someday let you tailor the dose to your own genes.
Marcondes-de-Castro. Ilitch A IA; Marinho. Thatiany S TS; Aguila. Marcia B MB; Mandarim-de-Lacerda....
In a mouse study that mimics obesity, type‑2 diabetes and menopause, daily tirzepatide kept the liver’s structure intact and helped the tiny power plants inside liver cells (mitochondria) stay healthy. It did this by balancing the processes that build, break down, and clean up mitochondria, and by boosting antioxidant defenses.
Ma. Tianyi T; Song. Fanfan F; Pan. Yongning Y; He. Ying Y; Cao. Xinming X; Zhang. Yan Y; Song. Guang...
In mice fed a high‑fat, high‑fructose diet, both semaglutide (a GLP‑1 drug) and tirzepatide (a dual GIP/GLP‑1 drug) lowered body weight, improved blood fats and insulin sensitivity. Tirzepatide changed fewer genes in brown fat but hit some inflammation‑related genes that semaglutide didn’t, hinting it might have extra anti‑inflammatory benefits.
Wiszniewski. Kacper K; Grudniewska. Anna A; Szabłowska-Gadomska. Ilona I; Pilichowska-Paszkiet...
The paper explains that the fat around the heart (epicardial adipose tissue) gets bigger in obesity and can damage the heart’s structure and rhythm. New weight‑loss drugs like GLP‑1 agonists and the dual GLP‑1/GIP drug tirzepatide may shrink this fat and protect the heart, but solid clinical proof is still missing.
Koceva. Andrijana A; Janež. Andrej A; Jensterle. Mojca M
The review says that tirzepatide and similar incretin drugs, which are already used for weight loss and diabetes, might also help keep muscle healthy. In animal studies they seem to reduce muscle wasting, improve muscle cell growth, boost mitochondria, and lower fat inside muscles. Human data are still limited, but the drugs appear to cause a proportional loss of fat and lean mass, suggesting they don’t dramatically shrink muscle when you lose weight.
The paper says that when you don’t get enough sleep or your internal clock is off, the hormones that help control blood sugar (GLP‑1 and GIP) don’t follow their normal daily pattern. This can make it harder to manage weight and glucose. The drug tirzepatide, which mimics both GLP‑1 and GIP, has even been cleared by the FDA to treat obstructive sleep apnea, hinting it might help when sleep problems and metabolism clash.
Akwe. Joyce J; Fongeh. Kimela K; Jung. Sarah S; Hall. Mary Ann Kirkconnell MAK; Patidar. Viniya V; S...
Obesity is a tough, chronic condition. Changing diet and activity alone helps a little, but adding medicines—especially the new dual drug tirzepatide—can produce much bigger weight loss, though we still need more long‑term safety data. Surgery still gives the biggest, most lasting loss but comes with higher immediate risks and costs. The best results come from tailoring a mix of lifestyle, drugs, and possibly surgery to each person.
Kellner. David A DA; Dente. Elizabeth E; Tran. Vincent V; Welsh. Travis T; Tran. Victor V; Saha. Ang...
A review of medical records found that people with rheumatoid arthritis who took GLP‑1 drugs like tirzepatide lost weight, had lower blood sugar and cholesterol, and also showed less joint inflammation and pain compared to similar patients who didn’t take the drug. About one‑third stopped the medication because of stomach upset.
Fredrick. Thomas Ward TW; Camilleri. Michael M; Acosta. Andres A
The review summarizes the latest anti‑obesity drugs up to February 2025, focusing on how they work and how well they help people lose weight. It highlights tirzepatide—a drug that activates both GLP‑1 and GIP receptors—as a strong weight‑loss option compared with older meds like orlistat or phentermine‑topiramate.
Ipaye. Testimony T; Goldney. Jonathan J; Wilkinson. Thomas J TJ; Zaccardi. Francesco F; Yates. Thoma...
In a large real‑world study, people with type‑2 diabetes who were overweight or obese and took tirzepatide lost weight and showed a trend toward fewer obesity‑related cancers compared with those on older diabetes pills, though the overall cancer reduction wasn’t statistically solid. The only clear cancer benefit was a much lower chance of ovarian cancer.
In a single person, taking tirzepatide was linked to more intense food cravings, and brain recordings showed a rise in low‑frequency activity in a reward‑center (the nucleus accumbens) right before those cravings. This hints that the drug can affect brain circuits that drive eating urges.
Altabas. Velimir V; Marinković Radošević. Jelena J
Scientists reviewed studies to see how diabetes medicines, including tirzepatide, change tiny gene‑regulating molecules called miRNAs. They found that these drugs do alter miRNA levels, and some changes might hint at how well a person will respond, but the data are still limited and not reliable enough for everyday use.
Polisky. Michael M; Kamel. Dina D; Ku. Jeong-Hee JH
A 63‑year‑old woman with obesity started tirzepatide for weight loss and then experienced severe low blood sugar after meals. Doctors discovered she actually had an insulin‑producing tumor (insulinoma), which the drug made the hypoglycemia worse. The report shows that tirzepatide can reveal hidden insulinomas and cause dangerous drops in blood sugar.
Viana. Diogo Pinto da Costa DPDC; Invitti. Adriana Luckow AL; Schor. Eduardo E
The review talks about tirzepatide, a drug already used for obesity and diabetes, and suggests it might help treat lipedema—a painful, stubborn fat condition in women—by reducing inflammation, fibrosis, and improving fat metabolism. However, there are no direct human studies yet, just mechanistic and related disease data.
Schmickl. Christopher N CN; Tripipitsiriwat. Athiwat A; Mokhlesi. Babak B; Mallampalli. Monica M; No...
A recent survey asked US adults with obesity and sleep apnea, plus sleep doctors, how they feel about using CPAP machines versus the weight‑loss drug tirzepatide. Most people think both are okay, but patients lean toward tirzepatide while doctors still favor CPAP. Both groups want more safety, cost, and long‑term data before choosing.
Fadhil. Nasrin M NM; Kadhim. Jawad Hasan JH; Atwan. Hatham W HW; Alwan. Huda A HA; Atwan. Zeenah W Z...
In lab tests, tirzepatide (a drug used for diabetes and weight loss) changed the activity of several genes in colon cancer cells. It boosted the tumor‑suppressor p53 and the cell‑death gene CASP8, while also raising the inflammation‑related NF‑kB and the growth gene c‑Myc. These mixed signals hint that tirzepatide might influence cancer‑related pathways, but the work was done only in a petri dish.